羟基喜树碱联合化疗治疗晚期非小细胞肺癌的临床观察  

Clinical observation of the hydroxycamptothecin based on combination chemotherapy in advanced non-small cell lung cancer

作　　者：孙文辉[1] 吴昌平[1] 朱丽娜[1] 

机构地区：[1]苏州大学附属第三医院肿瘤科,常州213003

出　　处：《中国肿瘤临床与康复》2003年第3期229-230,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的 观察羟基喜树碱联合化疗治疗晚期非小细胞肺癌的疗效和毒副作用。方法 56例晚期非小细胞肺癌患者中,50例肺腺癌接受HEMe方案化疗,6例肺鳞癌接受HE方案化疗。结果 总有效率为39.3％,肺腺癌有效率为42.0％,肺鳞癌有效率为16.7％。结论 羟基喜树碱联合化疗治疗非小细胞肺癌疗效好,毒副作用小,费用低,值得临床推广应用。Objective To evaluate the efficacy and safety profile of 10-hydroxycamptothecin based on combination chemotherapy in advanced non-small cell lung cancer (NSCLC) .Methods Of 56 NSCLC patients, 50 cases of lung adenocarcinoma were treated with HEMe and 6 cases of squamous cell carcinoma with HE regimens. Results In adenocarcinoma patients 21 cases achieved partial response(42.0%),and in squamous cell carcinoma patients 1 achieved partial response (16.7%). The overall response rate was 39.3 % . Conclusion 10-hydroxycamptothecin based on combination chemotherapy is active and tolerable in advanced NSCLC.

关 键 词：羟基喜树碱 化疗 联合治疗 晚期非小细胞肺癌 疗效 毒副作用 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]